The prothrombin complex concentrates market sales are anticipated to increase from a projected US$ 772.0 million in 2023 to a valuation of US$ 1.2 billion by 2033. Prothrombin complex concentrate is predicted to see consistent growth in demand, with China, India, the US, and the UK emerging as major manufacturers at a 4.1% CAGR.
The market for PCC has seen steady growth due to several factors, including an increase in the prevalence of bleeding disorders, rising surgical procedures, and the expanding geriatric population. Additionally, advancements in PCC formulations, such as the development of virus-inactivated concentrates, have improved safety profiles, further driving market expansion.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-7032
Prothrombin Complex Concentrates (PCC) are critical therapeutic agents used to treat bleeding disorders, primarily in patients with deficiencies in clotting factors. They play a vital role in managing hemorrhages caused by congenital coagulation factor deficiencies, liver diseases, and vitamin K antagonists. The increasing prevalence of bleeding disorders, coupled with rising surgical procedures and trauma cases, is driving the demand for PCC.
Key factors contributing to the anticipated growth of the Prothrombin Complex Concentrates market include advancements in the healthcare infrastructure, a rise in awareness about bleeding disorders, and the development of innovative PCC formulations. Additionally, a growing geriatric population and the increasing incidence of hemophilia and other clotting disorders are expected to fuel market expansion.
A new study by the company titled ‘Prothrombin Complex Concentrates Market: Global Industry Analysis 2013 to 2017 and Opportunity Assessment 2018 to 2028’, has listed out the key points being considered by the companies operating in the prothrombin complex concentrates market to emerge and stay sustainably profitable in the long run. The North America prothrombin complex concentrates market is projected to expand at a CAGR of 3.5% over the forecast period. North America and Western Europe are expected to be dominant markets for prothrombin complex concentrates, as most of the manufacturing facilities of prothrombin complex concentrates are located in these regions. However, the increasing demand for optimized & sustainable healthcare in countries of Asia Pacific, such as China and India, and of Middle-East is expected to fuel the growth of the prothrombin complex concentrates market.
The report finds the players operating in the market are laying emphasis on improving treatment options for patients with hemophilia B.
Treatment with prothrombin complex concentrates is an economical option for warfarin reversal. It is has been observed that the treatment with prothrombin complex concentrates is the most economical option as it minimizes the hospital stay and laboratory costs. Direct healthcare costs including drug and hospital costs in Europe are approximately US$ 400,000 for prothrombin complex concentrates, whereas for warfarin withdrawal therapy, it was approximated US$ 1,200,000.
Manufacturers tend to depend on plasma as a primary precursor to manufacture prothrombin complex concentrates, and in the past, they relied on third-party sources for plasma. Manufacturers are now opening their own plasma collection banks to reduce dependence on third-party sources. This trend has been observed to have grown since 2013. The key players operating in the market, such as CSL Behring & Shire, have scaled up their focus on depending on their own sources for plasma.
Keytakeways:
1.Essential Hemostatic Support: Prothrombin Complex Concentrates (PCC) play a vital role in providing rapid and effective hemostatic support for individuals with clotting disorders.
2.Swift Reversal: PCC offers a rapid reversal of anticoagulant effects, making it crucial in emergency situations, such as bleeding events or urgent surgical interventions.
3.Diverse Indications: Widely used across diverse indications including hemophilia, vitamin K deficiency, and warfarin-related bleeding, PCC demonstrates its versatility.
4.Improved Patient Outcomes: PCC’s ability to rapidly restore normal clotting factors contributes to improved patient outcomes by reducing bleeding risks.
5.Convenience in Dosage: PCC’s concentrated form allows for lower volumes of administration, minimizing fluid overload concerns during treatment.
6.Precise Coagulation Restoration: PCC’s specific coagulation factor composition ensures targeted and accurate restoration of clotting factors.
7.Advances in Safety: Ongoing advancements in PCC manufacturing processes enhance safety profiles, reducing the risk of adverse events.
8.Broader Accessibility: Expanding awareness and adoption of PCC globally facilitate improved accessibility to life-saving clotting factor therapy.
Request Report Methodology:https://www.futuremarketinsights.com/request-report-methodology/rep-gb-7032
Competitive Environment :
Companies use a variety of strategies to increase their market share. These are some examples:
Strategic alliances and collaborations: Many businesses are forming alliances and collaborations with other businesses in order to broaden their market reach, develop new products, and improve their manufacturing capabilities. For example, Sanquin and Octapharma announced a long-term collaboration in 2021 to develop and manufacture prothrombin complex concentrates for the treatment of bleeding disorders.
Product differentiation and innovation: Many companies are working to create new and innovative prothrombin complex concentrates that provide improved efficacy, safety, and patient convenience. CSL Behring, for example, received FDA approval for its Idelvion product in 2020, which is a longer-acting factor IX therapy that can be administered less frequently than traditional prothrombin complex concentrates.
Market expansion: Many businesses strive to expand their market.
Key Segments :
Distribution Channel:
•Compound Pharmacies
•Retail Pharmacies
•Hospital Pharmacies
Region:
•North America
•Latin America
•Europe
•APEJ
•Middle East & Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
